Latest Conference Coverage

The chief medical officer at Cognito Therapeutics talked about a medical device designed to slow cognitive decline in patients with Alzheimer disease through gamma frequency brain stimulation. [WATCH TIME: 6 minutes]

Compared with the standard dosing arm, those on an enhanced titration dosing of donanemab demonstrated a 41% reduction in the relative risk of ARIA-E.

Despite a small cohort sample size, treated patients with E2814 demonstrated significant reductions in p-tau217 after 12 weeks of treatment, sustained through the 108-week time point.

Melissa Spencer, PhD, gave commentary on her presentation from AANEM 2024, highlighting the emerging role of adeno-associated virus as a delivery system for gene therapies targeting muscular dystrophies.

Prior to the 2025 MDA Conference, the vice president of Public Policy & Advocacy at the Muscular Dystrophy Association talked about the increasing interest in gene therapy in the field of neuromuscular diseases.

In a small sample population of adolescents with myasthenia gravis, nipocalimab met its primary end point, showing a significant reduction in total serum immunoglobuin over a 24-week period.

The director of the myasthenia gravis clinic at Yale University provided additional insight on the MINT study of inebilizumab in myasthenia gravis, some of the subanalyses within, and next plans in the drug’s development. [WATCH TIME: 5 minutes]

The chief medical officer at Immunic provided clinical insight on the dual mechanism of action of vidofludimus calcium, and how its positioned as a treatment option across all MS subtypes. [WATCH TIME: 3 minutes]

David Devos, MD, PhD, a neuropharmacologist at the University of Lille, in France, discussed positive data from an early-stage study assessing InBrain Pharma’s device-assisted therapy in Parkinson disease.

The senior scientist at Sunnybrook Research Institute in Toronto, Ontario, provided clinical insight on his lecture given at AANEM 2024, focusing on the challenges and opportunities of teaching the next generation of practitioners.

The 2024 revisions to the McDonald diagnostic criteria for multiple sclerosis (MS) mark a significant advancement in the early detection and diagnosis of the disease, with new biomarkers and a broadened scope that may lead to earlier intervention and improved patient outcomes.

Constantine Farmakidis, MD, an associate professor of neurology at the University of Kansas Medical Center, provided clinical commentary on a subanalysis of a phase 3 study assessing nipocalimab, an investigational agent, in generalized myasthenia gravis.

Study investigator Henry Kaminski, MD, provided clinical insight on a unique trial assessing the efficacy and safety of oral cladribine tablets, an FDA-approved medication for multiple sclerosis, in patients with myasthenia gravis.

A recent analysis of the phase 3 ADHERE trial demonstrated the clinical benefit of subcutaneous efgartigimod PH20 in patients with chronic inflammatory demyelinating polyneuropathy.

Tuan Vu, MD, a professor of neurology at the University of South Florida, provided brief commentary on topline data of the phase 3 VIVACITY-MG3 study presented at AANEM 2024.

The phase 3 study is expected to include 110 patients with seronegative myasthenia gravis who will be randomly assigned to IV efgartigimod or placebo for a 5-week follow-up, followed by an open-label extension.

A new analysis revealed zilucoplan’s long-term efficacy and safety in patients with generalized myasthenia gravis, with data extending to 120 weeks of treatment.

The assistant professor of neurology at Wake Forest School of Medicine provided clinical insight on MG0020, a phase 3 trial assessing a self-administration of rozanolixizumab through a syringe driver. [WATCH TIME: 3 minu]

Despite balanced baseline characteristics, patients ranged from low to high number of rozanolixizumab treatment cycles, suggesting the need for a personalized approach.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Claassen, MD, MS. [LISTEN TIME: 14 minutes]

Findings showed that both fixed cycles and every-other-week dosing regimens of efgartigimod were well tolerated and effective in improving clinical outcomes in patients with generalized myasthenia gravis.

The PREVAIL trial, presented at the 2024 AANEM meeting, is investigating gefurulimab, a bispecific nanoantibody designed to inhibit complement activation, as a potential treatment for patients with generalized myasthenia gravis.

The neuromuscular specialist at the University of Tennessee Medical Center provided clinical insight on a retrospective analysis studying the long-term corticosteroid patterns of approved treatments for generalized myasthenia gravis. [WATCH TIME: 5 minutes]

Rozanolixizumab demonstrated efficacy in patients with generalized myasthenia gravis aged at least 65 years, despite a higher incidence of comorbidities observed in this population.

The Meta A. Neumann Professor of Neurology at George Washington University provided an overview of a new phase 3 study testing the efficacy and safety of cladribine versus placebo in generalized myasthenia gravis. [WATCH TIME: 3 minutes]

Pozelimab and cemdisiran work together to block the complement pathway, which plays a key role in gMG, using two different approaches—one suppresses liver production of a key protein, while the other targets it directly with antibodies.

Zilucoplan, approved for generalized myasthenia gravis in 2023, showed consistent complement inhibition, even with additional treatments like IVIg or plasma exchange.

The director of the myasthenia gravis clinic at Yale University provided clinical insight on promising phase 3 data assessing inebilizumab, an FDA-approved therapy for NMOSD, in patients with myasthenia gravis. [WATCH TIME: 4 minutes]